Telmisartan

Telmisartan is an ARB (angiotensin II receptor blocker), a medicine taken by mouth. The US label read, for telmisartan tablets (a generic product), lists two uses: treating high blood pressure, and reducing the risk of heart attack (myocardial infarction), stroke or cardiovascular death in patients 55 or older at high risk who are unable to take ACE inhibitors. The label read is a generic product label; the brand names for this substance are recorded as aliases.

Also called Micardis

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 73494; UNII U5SYW473RQ. UNII U5SYW473RQ is the UNII of the substance as the label names it. MeSH descriptor D000077333 is Telmisartan. Class: Angiotensin 2 Receptor Blocker (FDA established pharmacologic class, RxClass). The label read is the Ascend Laboratories, LLC label for telmisartan tablets, application ANDA205150, effective 2025-03-29 in openFDA; Drugs@FDA lists the application's sponsor as ADAPTIS. The brand label for Micardis (listed as discontinued in Drugs@FDA), other generic telmisartan labels and the combination labels were not used. This page records label indications and the class only: no trial result and no dose is given.

Trials at a glance

The figures count the 11 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.

Trials
11
Phase 3 or 4
9
Recruiting
0
Regulatory decisions
0
Trials by phase (rows) and registry status (columns)
PhaseNot yet recruitingCompletedUnknown statusAll statuses
Phase 20202
Phase 30404
Phase 41225
All phases18211

Conditions these trials study

Sponsors with the most trials

The lead sponsor of each trial, as the registry names it.

And 3 more.

About this drug

Level
Substance
Mechanism
Not reported

Claims and evidence

Context Patients for whom the US label of telmisartan tablets lists an indication: hypertension, cardiovascular risk reduction in patients 55 or older at high risk who are unable to take ACE inhibitors

Recipient
Recipient not specified
Population
Patients described in the indications section of the label. The risk reduction indication names patients 55 years of age or older at high risk who are unable to take ACE inhibitors; the hypertension indication does not state an age range.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
55 years or older for the risk reduction indication, as the passage read states; not stated for hypertension
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
Included
  • Patients with hypertension
  • Patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take ACE inhibitors
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of telmisartan tablets, USP, in the Ascend Laboratories, LLC version dated 2025-03-29 in openFDA (a generic product), lists the medicine for the treatment of hypertension, to lower blood pressure; and for reduction of the risk of heart attack (myocardial infarction), stroke or cardiovascular death in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take ACE inhibitors.

    Applies to Recipient not specified Patients for whom the US label of telmisartan tablets lists an indication: hypertension, cardiovascular risk reduction in patients 55 or older at high risk who are unable to take ACE inhibitors

    Certainty method
    Not assessed
    Limitations
    This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-09
    Next evidence check due
    Not scheduled
    Sources and citations (4)
    1. Supports openFDA drug label record for telmisartan tablets, USP, Ascend Laboratories, LLC label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 29bddc43-2809-4e1f-ae35-2865e15e9bb6 (manufacturer Ascend Laboratories, LLC, application ANDA205150), returned on 2026-11-09. The label text is dated 2025-03-29 (effective_time). Other openFDA records of telmisartan labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
      How it applies
      The label sentences that give the indications named in the statement, each quoted in the research quote table.
      Retrieved
      Source effective date
      2025-03-29
      Source state
      Current
      Version fingerprint
      13ec09d12943dd0899ef011d1e41530a3b174ce48e3dbf6df4fab4d2d936f9ee
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Supports openFDA drug label record for telmisartan tablets, USP, Ascend Laboratories, LLC label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 29bddc43-2809-4e1f-ae35-2865e15e9bb6 (manufacturer Ascend Laboratories, LLC, application ANDA205150), returned on 2026-11-09. The label text is dated 2025-03-29 (effective_time). Other openFDA records of telmisartan labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[1], 1.2 Cardiovascular Risk Reduction
      How it applies
      The label sentences that give the indications named in the statement, each quoted in the research quote table.
      Retrieved
      Source effective date
      2025-03-29
      Source state
      Current
      Version fingerprint
      13ec09d12943dd0899ef011d1e41530a3b174ce48e3dbf6df4fab4d2d936f9ee
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Background openFDA drug label record for telmisartan tablets, USP, Ascend Laboratories, LLC label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 29bddc43-2809-4e1f-ae35-2865e15e9bb6 (manufacturer Ascend Laboratories, LLC, application ANDA205150), returned on 2026-11-09. The label text is dated 2025-03-29 (effective_time). Other openFDA records of telmisartan labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20250329.
      Retrieved
      Source effective date
      2025-03-29
      Source state
      Current
      Version fingerprint
      13ec09d12943dd0899ef011d1e41530a3b174ce48e3dbf6df4fab4d2d936f9ee
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    4. Background openFDA Drugs@FDA record for application ANDA205150 (TELMISARTAN, sponsor ADAPTIS): product and sponsor

      Regulator · U.S. Food and Drug Administration (openFDA, Drugs@FDA) · Edition The openFDA Drugs@FDA record for application ANDA205150, returned on 2026-11-09. It lists the sponsor and the products of the application; only the first product listing is quoted.

      Locator
      results[0].products[0].brand_name
      How it applies
      Drugs@FDA product listing for application ANDA205150, which confirms the product the label belongs to.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      b4e8cbf33dbae999da26c62354a47273feb6e44843edb33850370266ed19bb56
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short values are quoted. The raw record is committed in the atlas repository.

FDA label

The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.

MICARDIS

No label from the application holder was found in the openFDA label dataset for application NDA020850. This page does not show another labeler's label in its place.

MICARDIS HCT

No label from the application holder was found in the openFDA label dataset for application NDA021162. This page does not show another labeler's label in its place.

TWYNSTA

No label from the application holder was found in the openFDA label dataset for application NDA022401. This page does not show another labeler's label in its place.

WIDAPLIK

No label from the application holder was found in the openFDA label dataset for application NDA219423. This page does not show another labeler's label in its place.

FDA decisions timeline

The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.

  1. Approval NDA020850 MICARDIS
  2. Approval NDA021162 MICARDIS HCT
  3. Supplemental approval NDA020850 MICARDIS
  4. Approval NDA022401 TWYNSTA
  5. Approval NDA219423 WIDAPLIK

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Registry records

Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.

Registry products 4

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.

    ProductNDA020850

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA021162

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA022401

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA219423

Registry trials 11

Record details

Record id
cardio:telmisartan
Content hash
a760ec635099a0180b5495d252d9e115c4efddd62fab90e479441b00110affec